EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability

Jonathan Boucher, Thibault Houles, Elsa Berliocchi, Geneviève Lavoie, Graham MacLeod, Marc K Saba-El-Leil, Stephane Angers, Sylvain Meloche, Philippe P Roux

Cell Reports · 2025

DOI: 10.1016/j.celrep.2025.116495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Jonathan Boucher und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada. Electronic address: jonathan.boucher@umontreal.…. Hauptthemen laut MEDLINE: Core Binding Factor Alpha 2 Subunit, Melanoma, Core Binding Factor beta Subunit, Cyclin-Dependent Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Santé, Cancer Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cutaneous melanoma is the deadliest form of skin cancer, frequently driven by hyperactivation of the RAS/mitogen-activated protein kinase (MAPK) pathway. Cyclin-dependent kinase 12 (CDK12), a downstream effector of MAPK signaling, has emerged as a therapeutic target due to its essential role in transcriptional regulation and DNA damage repair. To identify vulnerabilities associated with CDK12 inhibition, we performed a genome-wide CRISPR-Cas9 screen and identified the Runt-related transcription factor RUNX1 and its cofactor CBFβ as synthetic lethal partners of CDK12. RUNX1 inhibition enhanced melanoma sensitivity to CDK12 inhibitors in a p53-independent manner, resulting in DNA damage accumulation and impaired repair capacity. Combined inhibition of CDK12 and RUNX1 suppressed melanoma growth in vivo. These findings identify RUNX1/CBFβ as a compensatory mechanism in CDK12-inhibited melanoma and define a synthetic lethal interaction with translational potential for combinatorial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Core Binding Factor Alpha 2 SubunitMelanomaCore Binding Factor beta SubunitCyclin-Dependent KinasesGenomic InstabilitySkin NeoplasmsHumansAnimalsCell Line, TumorMiceDNA Damage

Stichwörter der Autor:innen

CBFBCDK12CP: cancerCRISP-Cas9 screeningDNA damage responseRUNX1genomic stabilitymelanomap53-independent pathwaytherapeutic vulnerabilitytranscriptional regulation

Substanzen

Core Binding Factor Alpha 2 SubunitCore Binding Factor beta SubunitCyclin-Dependent KinasesCDK12 protein, humanRUNX1 protein, humanCBFB protein, human

Autor:innen und Institutionen

  • Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada. Electronic address: jonathan.boucher@umontreal.ca.
  • Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada.
  • Donnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
  • Donnelly Centre for Cellular & Biomolecular Research, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Department of Bi…
  • Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada; Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada.
  • Institute for Research in Immunology and Cancer (IRIC), Université de Montréal, Montreal, QC, Canada; Department of Pathology and Cell Biology, Faculty of Medicine, Université de Montréal, Montreal, QC, Canada. Electron…

Förderung

  • CIHR
  • Santé
  • Cancer Research Society

Zitieren

APA

Boucher, J., Houles, T., Berliocchi, E., Lavoie, G., MacLeod, G., Saba-El-Leil, M. K., Angers, S., Meloche, S., & Roux, P. P. (2025). CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116495

Vancouver

Boucher J, Houles T, Berliocchi E, Lavoie G, MacLeod G, Saba-El-Leil MK, et al. CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116495

BibTeX
@article{Boucher2025,
  author = {Boucher, Jonathan and Houles, Thibault and Berliocchi, Elsa and Lavoie, Geneviève and MacLeod, Graham and Saba-El-Leil, Marc K and Angers, Stephane and Meloche, Sylvain and Roux, Philippe P},
  title = {CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability},
  journal = {Cell Reports},
  year = {2025},
  doi = {10.1016/j.celrep.2025.116495}
}
Kostenlos starten →